B&K Corporation Limited (02396.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 390.20M

MomentumView details →

1D Return

+4.44%

YTD Return

−70.93%

RSI (14)

51.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 390.20M

RSI (14)

51.1

MomentumView details →

1D Return

+4.44%

YTD Return

−70.93%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Qingcheng New Drug reported an interim loss of RMB 122 million for the six months ended June 2026, widening from RMB 86.68 million a year earlier, with no dividend declared.19d ago

Hua Ran Bio (02396.HK) announced that its stock short name will change to 'Qingcheng New Drug-B' from July 22, 2026.49d ago

Similar companies

Opus Genetics, Inc.IRD Century Therapeutics, Inc.IPSC Larimar Therapeutics, Inc.LRMR EyePoint Pharmaceuticals, Inc.EYPT Zentalis Pharmaceuticals, Inc.ZNTL Lexeo Therapeutics, Inc. Common StockLXEO Find similar companies →

Latest newsMore news →

Qingcheng New Drug reported an interim loss of RMB 122 million for the six months ended June 2026, widening from RMB 86.68 million a year earlier, with no dividend declared.19d ago Hua Ran Bio (02396.HK) announced that its stock short name will change to 'Qingcheng New Drug-B' from July 22, 2026.49d ago